Pivotal Trials Are Cheaper For Unmet Needs And Orphan Drugs, JAMA Study Finds
Executive Summary
Analysis of clinical trial costs for CDER’s 2015-2016 novel therapeutic approvals finds pivotal studies are most expensive when a new agent has a similar benefit to already marketed products with well-established clinical profiles.